Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Nitric Oxide in Lung Donors and Recipients to Prevent Reperfusion Injury
NCT00570245Phase 2Completed
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Apr 2005
- Primary completion
- Jun 2008
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
A Phase 2 trial of nitric oxide in reperfusion injury (IRI), sponsored by Mallinckrodt Pharmaceuticals. Started Apr 2005; status: completed.
02
Drugs
nitric oxide
03
Conditions
reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00570245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570245.